Author: Ya. V. Nikiforova, Government Institution «L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine»
Diseases of the gastrointestinal tract (GIT) occupy a significant place in the overall structure of somatic diseases worldwide. The largest group of chronic diseases of the digestive system are diseases of the gastroduodenal zone, among which, along with functional (functional dyspepsia (FD) — 20 % of the population) have a large proportion of inflammatory and destructive diseases (gastroesophageal reflux disease (GERD) — up to 40 % of the population, chronic gastritis and chronic duodenitis — 45 — 50 % of the population, peptic ulcer of the stomach and duodenum — 14 — 15 % of the population). Each of these diseases has its own features of etiopathogenesis and approaches to treatment. However, a common pathological factor contributing to the development of these nosologies is a violation of motor-evacuation function. The appointment of a group of drugs that normalize peristaltic activity is an integral part of the therapy of the above nosologies. The range of existing drugs with prokinetic activity against the gastrointestinal tract is quite large. All drugs discussed in this article have their
advantages and disadvantages.
One of the effective and safe prokinetics registered in October 2020 in Ukraine is the drug domperidone DOPROKIN (WORLD MEDICINE). This drug has proven effectiveness in the treatment of patients with FD, GERD, chronic gastritis, especially in comorbidity with Diabetes mellitus II (diabetic gastroparesis). DOPROKIN is available without a prescription. Indications for use are relief of symptoms of nausea and vomiting. The drug increases the pressure of the lower esophageal sphincter, esophageal clearance, reduces intragastric pressure. For adults, the recommended dose is 1 tablet (10 mg) 3 times a day (before meals for 15 — 30 minutes). The maximum daily dose is 30 mg.